Properties and mutation studies of a bacteriophage-derived chimeric recombinant staphylolytic protein P128

P128 is a chimeric anti-staphylococcal protein having a catalytic domain from a Staphylococcus bacteriophage K tail associated structural protein and a cell wall targeting domain from the Staphylococcus bacteriocin-lysostaphin. In this study, we disclose additional properties of P128 and compared the same with lysostaphin. While lysostaphin was found to get inactivated by heat and was inactive on its parent strain S. simulans biovar staphylolyticus, P128 was thermostable and was lytic towards S. simulans biovar staphylolyticus demonstrating a difference in their mechanism of action. Selected mutation studies of the catalytic domain of P128 showed that arginine and cysteine, at 40th and 76th positions respectively, are critical for the staphylolytic activity of P128, although these amino acids are not conserved residues. In comparison to native P128, only the R40S mutant (P301) was catalytically active on zymogram gel and had a similar secondary structure, as assessed by circular dichroism analysis and in silico modeling with similar cell binding properties. Mutation of the arginine residue at 40th position of the P128 molecule caused dramatic reduction in the Vmax (∆OD600 [mg/min]) value (nearly 270 fold) and the recombinant lysostaphin also showed lesser Vmax value (nearly 1.5 fold) in comparison to the unmodified P128 protein. The kinetic parameters such as apparent Km (Km APP) and apparent Kcat (KcatAPP) of the native P128 protein also showed significant differences in comparison to the values observed for P301 and lysostaphin.

[1]  S. Gupta,et al.  Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility. , 1992, The Journal of infectious diseases.

[2]  F. Götz,et al.  The Presence of Peptidoglycan O-Acetyltransferase in Various Staphylococcal Species Correlates with Lysozyme Resistance and Pathogenicity , 2006, Infection and Immunity.

[3]  C. Schindler,et al.  PURIFICATION AND PROPERTIES OF LYSOSTAPHIN--A LYTIC AGENT FOR STAPHYLOCOCCUS AUREUS. , 1965, Biochimica et biophysica acta.

[4]  J. Patel,et al.  Characterization of a Strain of Community-AssociatedMethicillin-Resistant Staphylococcus aureus WidelyDisseminated in the UnitedStates , 2006, Journal of Clinical Microbiology.

[5]  Alex Bateman,et al.  The CHAP domain: a large family of amidases including GSP amidase and peptidoglycan hydrolases. , 2003, Trends in biochemical sciences.

[6]  N. C. Price,et al.  How to study proteins by circular dichroism. , 2005, Biochimica et biophysica acta.

[7]  Chad W. Euler,et al.  A Novel Chimeric Lysin Shows Superiority to Mupirocin for Skin Decolonization of Methicillin-Resistant and -Sensitive Staphylococcus aureus Strains , 2010, Antimicrobial Agents and Chemotherapy.

[8]  W. Zygmunt,et al.  LYSOSTAPHIN: ENZYMATIC MODE OF ACTION. , 1965, Biochemical and biophysical research communications.

[9]  B. Berger-Bächi,et al.  Cell wall monoglycine cross-bridges and methicillin hypersusceptibility in a femAB null mutant of methicillin-resistant Staphylococcus aureus , 1997, Journal of bacteriology.

[10]  Gabriele Bierbaum,et al.  Lytic Activity of Recombinant Bacteriophage φ11 and φ12 Endolysins on Whole Cells and Biofilms of Staphylococcus aureus , 2006, Applied and Environmental Microbiology.

[11]  F. Tenover,et al.  Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. , 2001, Emerging infectious diseases.

[12]  M. A. Andrade,et al.  Evaluation of secondary structure of proteins from UV circular dichroism spectra using an unsupervised learning neural network. , 1993, Protein engineering.

[13]  G. Archer,et al.  Mechanism and Suppression of Lysostaphin Resistance in Oxacillin-Resistant Staphylococcus aureus , 2001, Antimicrobial Agents and Chemotherapy.

[14]  H. Labischinski,et al.  Cell Wall Composition and Decreased Autolytic Activity and Lysostaphin Susceptibility of Glycopeptide-Intermediate Staphylococcus aureus , 2004, Antimicrobial Agents and Chemotherapy.

[15]  G. Waldo,et al.  Directed evolution of an extremely stable fluorescent protein. , 2009, Protein engineering, design & selection : PEDS.

[16]  O. Schneewind,et al.  Target cell specificity of a bacteriocin molecule: a C‐terminal signal directs lysostaphin to the cell wall of Staphylococcus aureus. , 1996, The EMBO journal.

[17]  R. Sleator,et al.  In silico modeling of the staphylococcal bacteriophage-derived peptidase CHAPK , 2011, Bacteriophage.

[18]  James M Aramini,et al.  Structural elucidation of the Cys‐His‐Glu‐Asn proteolytic relay in the secreted CHAP domain enzyme from the human pathogen Staphylococcus saprophyticus , 2009, Proteins.

[19]  Michael Y. Galperin,et al.  Amidase domains from bacterial and phage autolysins define a family of gamma-D,L-glutamate-specific amidohydrolases. , 2003, Trends in biochemical sciences.

[20]  P. Tulkens,et al.  Contrasting Effects of Acidic pH on the Extracellular and Intracellular Activities of the Anti-Gram-Positive Fluoroquinolones Moxifloxacin and Delafloxacin against Staphylococcus aureus , 2010, Antimicrobial Agents and Chemotherapy.

[21]  M. Bochtler,et al.  Anti-staphylococcal activities of lysostaphin and LytM catalytic domain , 2012, BMC Microbiology.

[22]  Beatriz Martínez,et al.  Bacteriophage virion-associated peptidoglycan hydrolases: potential new enzybiotics , 2013, Critical reviews in microbiology.

[23]  L. Heath,et al.  The lysostaphin endopeptidase resistance gene (epr) specifies modification of peptidoglycan cross bridges in Staphylococcus simulans and Staphylococcus aureus , 1995, Applied and environmental microbiology.

[24]  Yuan-chuan Lee,et al.  Determination of lysozyme activities in a microplate format. , 2002, Analytical biochemistry.

[25]  A. Sulakvelidze,et al.  Bacteriophage Therapy in Humans , 2004 .

[26]  S. Ruzal,et al.  Murein Hydrolase Activity in the Surface Layer of Lactobacillus acidophilus ATCC 4356 , 2008, Applied and Environmental Microbiology.

[27]  Piero Fariselli,et al.  ConSeq: the identification of functionally and structurally important residues in protein sequences , 2004, Bioinform..

[28]  G. Archer,et al.  Lysostaphin Treatment of Experimental Methicillin-Resistant Staphylococcus aureus Aortic Valve Endocarditis , 1998, Antimicrobial Agents and Chemotherapy.

[29]  S. Padmanabhan,et al.  Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection , 2011, BMC Microbiology.

[30]  Shogo Nakamura,et al.  The two-component cell lysis genes holWMY and lysWMY of the Staphylococcus warneri M phage varphiWMY: cloning, sequencing, expression, and mutational analysis in Escherichia coli. , 2005, Gene.

[31]  M. Finland,et al.  Altered Cell Walls of Staphylococcus aureus resistant to Methicillin , 1970, Nature.

[32]  Ioannis Xenarios,et al.  T-Coffee: a web server for the multiple sequence alignment of protein and RNA sequences using structural information and homology extension , 2011, Nucleic Acids Res..

[33]  C. Schindler,et al.  LYSOSTAPHIN: A NEW BACTERIOLYTIC AGENT FOR THE STAPHYLOCOCCUS. , 1964, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Raj,et al.  Antistaphylococcal activity of bacteriophage derived chimeric protein P128 , 2012, BMC Microbiology.

[35]  B. Martínez,et al.  Lytic activity of the virion-associated peptidoglycan hydrolase HydH5 of Staphylococcus aureus bacteriophage vB_SauS-phiIPLA88 , 2011, BMC Microbiology.

[36]  J. Weiner,et al.  Enhanced antimicrobial activity of engineered human lysozyme. , 2010, ACS chemical biology.

[37]  J. Reilly,et al.  Comprehensive Characterization of Methicillin-resistant Staphylococcus aureus subsp. aureus COL Secretome by Two-dimensional Liquid Chromatography and Mass Spectrometry* , 2010, Molecular & Cellular Proteomics.

[38]  J. Engler,et al.  The bifunctional peptidoglycan lysin of Streptococcus agalactiae bacteriophage B30. , 2004, Microbiology.

[39]  R. Nussinov,et al.  Factors enhancing protein thermostability. , 2000, Protein engineering.

[40]  Torsten Schwede,et al.  BIOINFORMATICS Bioinformatics Advance Access published November 12, 2005 The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling , 2022 .

[41]  L. Heath,et al.  Plasmid-encoded lysostaphin endopeptidase gene of Staphylococcus simulans biovar staphylolyticus , 1987 .

[42]  A. Conde Staphylococcus aureus infections. , 1998, The New England journal of medicine.

[43]  R. Edwards,et al.  Genome of Staphylococcal Phage K: a New Lineage of Myoviridae Infecting Gram-Positive Bacteria with a Low G+C Content , 2004, Journal of bacteriology.

[44]  A. Lepeuple,et al.  Analysis of the Bacteriolytic Enzymes of the Autolytic Lactococcus lactis subsp. cremorisStrain AM2 by Renaturing Polyacrylamide Gel Electrophoresis: Identification of a Prophage-Encoded Enzyme , 1998, Applied and Environmental Microbiology.

[45]  Jiya Y. Asrani,et al.  A novel bacteriophage Tail-Associated Muralytic Enzyme (TAME) from Phage K and its development into a potent antistaphylococcal protein , 2011, BMC Microbiology.

[46]  R. Daum,et al.  Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate. , 2001, The Journal of antimicrobial chemotherapy.

[47]  L. Zhijun,et al.  Efficient Adsorption of Lysostaphin on Bacterial Cells of Lysostaphin‐Resistant Staphylococcus aureus Mutant , 1993, Microbiology and immunology.

[48]  Vivek Anantharaman,et al.  Evolutionary history, structural features and biochemical diversity of the NlpC/P60 superfamily of enzymes , 2003, Genome Biology.

[49]  R. Boom,et al.  Thermozymes and their applications , 2001, Applied biochemistry and biotechnology.

[50]  L. Heath,et al.  Plasmid-encoded lysostaphin endopeptidase resistance of Staphylococcus simulans biovar staphylolyticus. , 1989, Biochemical and biophysical research communications.

[51]  M. Lieberman,et al.  Virolysin: a virus-induced lysin from staphylococcal phage lysates. , 1955, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[52]  W. Zygmunt,et al.  Susceptibility of coagulase-negative staphylococci to lysostaphin and other antibiotics. , 1968, Applied microbiology.

[53]  Bruna Gonçalves Coutinho,et al.  Lysostaphin: A Staphylococcal Bacteriolysin with Potential Clinical Applications , 2010, Pharmaceuticals.

[54]  Ravisha Chikkamadaiah,et al.  Biochemical characterization and evaluation of cytotoxicity of antistaphylococcal chimeric protein P128 , 2012, BMC Research Notes.

[55]  W. Delano The PyMOL Molecular Graphics System , 2002 .